PaxVax and Valneva will market each other's cholera and typhoid vaccines; Scripps wins $4.5M from Gates Foundation for HIV/AIDS vaccine;

> PaxVax and Valneva have entered into an agreement to market their cholera and typhoid vaccines. PaxVax will market Valneva's Dukoral in Italy, Spain and Portugal, and Valneva will market PaxVax's Vivotif in Canada, Sweden, Norway, Denmark and Finland. Release

> The Scripps Research Institute won two grants from the Bill & Melinda Gates Foundation totaling more than $4.5 million to fund the development of an HIV/AIDS vaccine. Release

> Gaithersburg, MD-based Vaxin announced the enrollment of its first patient into a Phase I trial of HepTcell, its hepatitis B candidate. Release

Suggested Articles

Having struck two COVID-19 vaccine supply deals already, EU officials are in discussions with Novavax, as well.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.